NSCLC metastatic/no molecular target

 
Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 10/10/2019)

1st line
LUNG037 (Merck)
A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer.

ORION (AstraZeneca)
A randomized, double-blind, multi-center, global Phase II study to determine the efficacy and safety of Durvalumab plus Olaparib combination therapy compared with Durvalumab monotherapy as maintenance therapy in patients whose disease has not progressed following Standard of Care platinum-based chemotherapy with Durvalumab as first-line treatment in patients with Stage IV NSCLC with tumors that lack activating EGFR mutations and  ALK fusions.

PDC-LUNG-101 (PDC*line)
An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with NSCLC.

2th line 
Currently no trials

3th line 
Currently no trials